Pitt Study Reveals Simple Intervention Benefitting Cancer Patients and Saving Hospitals Money
Cancer patients who received specialized mental health support as part of their treatment plan are more likely to see improvements in their quality of life and reductions in pain, depression and fatigue, according to a study led by researchers at the University of Pittsburgh School of Medicine.
In addition to lasting improvements in patients’ quality of life, researchers observed lower risk of cardiovascular disease in family caregivers, as well as substantial cost savings to the healthcare system. The findings from a Phase III clinical trial were published today in The Lancet.
“The current standard of care, which includes screening patients for these symptoms and referring them to a provider for treatment, is not working,” said lead author of the study Jennifer Steel, Ph.D., professor of surgery, psychiatry and psychology at Pitt. “Our integrated screening and treatment program provides meaningful support to patients and can save hospitals millions of dollars by preventing readmissions.” Jennifer Steel PhD
Numerous studies have shown that symptoms such as depression and pain are associated with higher rates of emergency room visits and readmissions to the hospital, higher health care costs and poorer survival. For nearly two decades, screening for these symptoms and referral for treatment has become standard of care for cancer centers in the U.S., Canada, Europe and Australia. Yet, various barriers prevent the majority of patients from initiating treatment. Steel and her team wanted to change that.
Out of 459 participants in the Phase III trial that was run at UPMC Hillman Cancer Center in Pittsburgh, half was assigned to the integrated screening and stepped collaborative care intervention group and connected with a trained social worker or counselor for weekly Cognitive Behavioral Therapy (CBT) sessions. Those sessions were integrated into the cancer care plan and held weekly for at least eight to 12 weeks via telehealth. Patients were also offered medication treatment if CBT alone did not provide a substantial benefit.
Traditional strategies involved with CBT include identifying and changing automatic thoughts, relaxation techniques, and changing core beliefs about oneself or environment. The CBT sessions also focused on the reduction of pain and fatigue by improving sleep hygiene and increasing physical activity.
At the six-month follow up, patients who were assigned to the stepped collaborative care group had greater improvements in emotional, physical and functional well-being than patients who were referred to a provider in their community for treatment. Importantly, those improvements persisted even one year after the intervention was initiated.
Patients receiving mental health treatment also had fewer emergency room visits and readmissions within 90 days, and shorter hospital stays, thus cutting down on costs to the health care system. The study showed that, even if the collaborative care intervention was offered to patients for free, hospitals may expect to save upward of 4 million dollars for every 250 patients. It is the first U.S.-based collaborative care intervention in the context of cancer to show such cost savings.
“Preserving, or improving, quality of life while undergoing treatment for cancer is our goal, and for some patients, it is as important as survival,” said Steel. “We hope our findings may shift the paradigm in the way in which we screen and treat these symptoms, while at the same time provide meaningful support to patients.”
Additional authors of the study include Charles George, M.S., Lauren Terhorst, Ph.D., Jonathan G. Yabes, Ph.D., Dan P. Zandberg, M.D., Marci Nilsen, Ph.D., Jonas Johnson, M.D., Yoram Vodovotz, Ph.D., Jon Walker, Ph.D., Samer Tohme, M.D., Timothy Billiar, M.D., and David A. Geller, M.D., all of Pitt; Vincent Reyes, M.D., Gauri Kiefer, M.D., Christopher Marsh, M.D., Jason Bierenbaum, M.D., Nishant Tageja, M.D., Michal Krauze, M.D., Robert VanderWeele, M.D., Gaurav Goel, M.D., and Gopala Ramineni, M.D., all of UPMC Hillman Cancer Center, and Michael Antoni, Ph.D., of the University of Miami.